Trials / Completed
CompletedNCT00634205
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
A Phase II Study Assessing the Activity of Valproate Acid Plus Doxorubicin in Refractory or Recurrent Malignant Mesothelioma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- European Lung Cancer Working Party · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valproate plus doxorubicin | Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2009-03-01
- Completion
- 2010-06-01
- First posted
- 2008-03-12
- Last updated
- 2015-02-12
Locations
8 sites across 2 countries: Belgium, France
Source: ClinicalTrials.gov record NCT00634205. Inclusion in this directory is not an endorsement.